Devendra Hiwase
Adelaide Medical School
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Qualifications: MBBS, MD, FRACP, FRCPA, PhDPractice Responsibilities: Clinical and laboratory haematologySpecialities: Malignant haematology and stem cell transplantationSite: Royal Adelaide Hospital (RAH), Haematology DepartmentA/Prof Devendra Hiwase is a Consultant Haematologist at the Royal Adelaide Hospital, Senior Lecturer, University of Adelaide and Senior Research Fellow at South Australia Health Medical Research Institute (SAHMRI). He has a special interest in myelodysplastic syndromes (MDS), acute myeloid leukaemia (AML) and stem cell transplantation. In 2012, he started the MDS Research Group and South Australian MDS (SA-MDS) registry. Currently, the Group is involved in clinical and translational research projects, including mutational profiling, identifying novel biomarkers, and exploring the impact of nursing case management and comprehensive geriatric assessment on patients with MDS and related disorders.A/Prof Hiwase’s research focuses on the pathogenesis of myeloid neoplasms and has presented his research findings in multiple international and national meetings and published in peer reviewed journals. He serves on the editorial board of Leukemia Research and as a reviewer for speciality journals such as Haematologica, Leukemia and Lymphoma, as well as British Journal of Haematology. He is also a subject expert reviewer (external) for NHMRC project grants and has made regular contributions to teaching, provision of specialist medical services, and involvement in local and national committees. Dr Hiwase is a fellow of RACP, RCPA and member of the Australasian Leukaemia and Lymphoma Group (ALLG), Haematology Society of Australasia and New Zealand (HSANZ), American Society of Hematology, and a steering committee member of the national MDS and Aplastic Anaemia registry.
Myeloid neoplasms including myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) are a group of blood cancers that frequently affect older people. Some patients develop MDS/AML after treatment for their primary cancer (i.e. prostate cancer, breast cancer). This group of patients are known as having therapy-related myeloid neoplasms (T-MN). There are very limited treatment options for T-MN and the survival of these patients is poor. The MDS/AML Research Group focuses on improving the clinical outcome of patients by optimising current therapies and developing new therapies.
Our research group is split into two main arms of MDS/AML research – clinical research and basic science research. The clinical team focuses on patients’ health-related issues including developing global assessment tools to assess patients’ psycho-social needs, quality of life, overall health issues, and treatment-related toxicity. We also aim to improve treatment strategies by studying other factors, such as the management of infections, transfusion support, geriatric support, anticoagulation bleeding support and autoimmune diseases. The basic science team focuses on understanding the molecular pathogenesis of MDS/AML and identify biomarkers (i.e. predisposing mutations, abnormal bone marrow environment caused by long-term chemotherapy and drug resistance proteins) which can potentially change management and developing novel therapeutic approaches.
-
Appointments
Date Position Institution name 2021 - ongoing Clinical Associate Professor The University of Adelaide -
Language Competencies
Language Competency English Can read, write, speak, understand spoken and peer review -
Research Interests
-
Journals
-
Book Chapters
Year Citation 2011 Hiwase, D. K., & Hughes, T. P. (2011). Therapy of Advanced-Stage and Resistant Chronic Myeloid Leukemia. In Leukemias Principles and Practice of Therapy (pp. 281-295). Wiley.
DOI2008 Hiwase, D. K., & Hughes, T. (2008). Monitoring response to therapy for patients with chronic myeloid leukemia. In Chronic Myeloproliferative Disorders (pp. 103-117). -
Conference Papers
Year Citation 2020 Ravandi, F., Pocock, C., Selleslag, D., Montesinos, P., Sayar, H., Musso, M., . . . Dombret, H. (2020). Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 Maintenance Therapy in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Trial. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 20 (pp. S187-S188). CIG MEDIA GROUP, LP.
WoS12019 Cheok, K. P. L., Chhetri, R., Wee, L. Y. A., Salvi, A., Mcrae, S., Roxby, D. J., . . . Hiwase, D. K. (2019). The Burden of Clinically Significant Bleeding, Thrombocytopenia and Platelet Transfusions in Myelodysplastic Syndromes. In BLOOD Vol. 134 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI2019 Sharplin, K., Wee, L. Y. A., Edwards, S., Danner, S., Yong, A. S., Singhal, D., & Hiwase, D. (2019). Outcomes and Healthcare Utilization in Older Patients with Acute Myeloid Leukemia (AML). In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 19 (pp. S224). CIG MEDIA GROUP, LP.
DOI2019 Singhal, D., Hahn, C. N., Moma, L. D., Wee, L. Y. A., Chhetri, R., Babic, M., . . . Hiwase, D. K. (2019). Deleterious Germline Variants, Especially in the DNA Repair Pathway, Are Common in Patients with Non-Related Multiple Cancers, One of Them Being Hematological Malignancy. In BLOOD Vol. 134 (pp. 3 pages). FL, Orlando: ELSEVIER.
DOI WoS12019 Brown, A. L., Babic, M., Schreiber, A., Feng, J., Dobbins, J., Arts, P., . . . Scott, H. S. (2019). Familial Clustering of Hematological Malignancies: Harbingers of Wider Germline Cancer Susceptibility. In BLOOD Vol. 134 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI2019 Hahn, C. N., Babic, M., Brautigan, P. J., Venugopal, P., Phillips, K., Dobbins, J., . . . Scott, H. S. (2019). Australian Familial Haematological Cancer Study - Findings from 15 Years of Aggregated Clinical, Genomic and Transcriptomic Data. In BLOOD Vol. 134 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS22019 Molga, A., Wall, M., Chhetri, R., Wee, A., Singhal, D., Giri, P., . . . Hiwase, D. K. (2019). An Observational Study of the Prescribing Practices and Patient Reported Outcomes Measures in Older People with Myelodysplastic Syndrome. In BLOOD Vol. 134 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS12019 Unnikrishnan, A., Lim, X. Y., Joshi, S., Nunez, A. C., Vaughan, L., Pickford, R., . . . Pimanda, J. (2019). <i>In Vivo</i> Assessment of Intracellular Dynamics Comparing Injection Versus Oral Azacitidine in a Phase IIb Investigator Initiated Clinical Trial. In BLOOD Vol. 134 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI2019 Kutyna, M., Paton, S., Gronthos, S., & Hiwase, D. (2019). ABERRANT BONE MARROW MICROENVIRONMENT IN THERAPY RELATED MYELOID NEOPLASM. In EXPERIMENTAL HEMATOLOGY Vol. 76 (pp. E3-E4). ELSEVIER SCIENCE INC. 2018 Shanmuganathan, N., Branford, S., Yong, A., Hiwase, D., Yeung, D., Ross, D., & Hughes, T. (2018). Predictors of Success in Treatment-Free Remission: A Single Centre Experience. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 18 (pp. S224). CIG MEDIA GROUP, LP.
DOI2017 Shanmuganathan, N., Branford, S., Yeung, D., Hiwase, D. K., Yong, A. S. M., Ross, D. M., & Hughes, T. P. (2017). Cumulative Incidence of Treatment-Free Remission (TFR) for Patients with Chronic Myeloid Leukemia (CML): The Adelaide Experience. In BLOOD Vol. 130 (pp. 3 pages). Atlanta, GA: AMER SOC HEMATOLOGY. 2017 Singhal, D., Kutyna, M. M., Chhetri, R., Wee, A., Hague, S., Nath, L., . . . Hiwase, D. K. (2017). Red Cell Alloimmunisation Is Associated with Development of Autoantibodies and Increased Red Cell Transfusion Requirements in Myelodysplastic Syndromes (MDS). In BLOOD Vol. 130 (pp. 3 pages). Atlanta, GA: AMER SOC HEMATOLOGY. 2017 Al-Kali, A., Hiwase, D., Baer, M. R., Greenberg, P., Shortt, J., Collins, R., . . . Silverman, L. R. (2017). Relationship of bone marrow blast (BMBL) response to overall survival (OS) in a multicenter study of rigosertib (Rigo) in patients (pts) with myelodysplastic syndrome (MDS) with excess blasts progressing on or after treatment with a hypomethylating agent (HMA). In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 5 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI WoS12017 Singhal, D., Wee, A., Parker, W., Moore, S., Babic, M., Feng, J., . . . Hiwase, D. K. (2017). Presence of Rare Germline Variants in Fanconi Anaemia Pathway Genes Confers a Poor Prognosis Comparable to <i>TP53</i> Mutations in Therapy-Related Myeloid Neoplasms. In BLOOD Vol. 130 (pp. 3 pages). Atlanta, GA: AMER SOC HEMATOLOGY.
WoS22017 Hahn, C. N., Wee, A., Babic, M., Feng, J., Wang, P., Kutyna, M. M., . . . Scott, H. S. (2017). Duplication on Chromosome 14q Identified in Familial Predisposition to Myeloid Malignancies and Myeloproliferative Neoplasms. In BLOOD Vol. 130 (pp. 2 pages). Atlanta, GA: AMER SOC HEMATOLOGY.
WoS32016 Schwarer, A. P., Wight, J., Jackson, K., Beligaswatte, A. M., Butler, J. P., Kennedy, G., . . . Marlton, P. (2016). High-Dose Cytarabine (HiDAC) Improves the Cure Rate of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Is It Better to be Given As Induction Therapy or As Consolidation Therapy?. In BLOOD Vol. 128 (pp. 4 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI WoS242016 Brown, A. L., Hahn, C. N., Carmichael, C., Wilkins, E., Babic, M., Chong, C. -E., . . . Scott, H. S. (2016). Expanded Phenotypic and Genetic Heterogeneity in the Clinical Spectrum of FPD-AML: Lymphoid Malignancies and Skin Disorders Are Common Features in Carriers of Germline <i>RUNX1</i> Mutations. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI WoS22016 Shanmuganathan, N., Branford, S., Braley, J., Hiwase, D., Yeung, D. T., Ross, D. M., & Hughes, T. P. (2016). For Patients with Sustained MR4-MR4.5, Less Frequent Molecular Monitoring during the First 12 Months after Tyrosine Kinase Inhibitor Cessation Is Viable for Timely Detection of Loss of MMR. In BLOOD Vol. 128 (pp. 7 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI2016 Yeung, D. T., Osborn, M. P., White, D. L., Branford, S., Gerber, T., Butcher, B., . . . Hughes, T. P. (2016). Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI2016 Garcia-Manero, G., Fenaux, P., Al-Kali, A., Navada, S. C., Baer, M. R., Raza, A., . . . Silverman, L. R. (2016). Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI WoS102016 Hiwase, D. K., Tan, P., D'Rozario, J., Taper, J., Powell, A. R., Irving, I., . . . Hughes, T. P. (2016). Efficacy and Safety of Nilotinib 300 Mg Twice Daily (BD) in Patients with CML in Chronic Phase (CML-CP) Who Are Intolerant to Prior BCR-ABL Tyrosine Kinase Inhibitors (TKIs): Results from the Randomized, Phase IIIb ENES Tswift Study. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI2016 Singhal, D., Strupp, C., Chhetri, R., Kutyna, M., Wee, L., Nath, S., . . . Germing, U. (2016). RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients: analysis of South Australian and Dusseldorf MDS registries. In Proceedings of the 58th Annual Meeting and Exposition of the American Society of Hematology, as published in Blood Vol. 128 (pp. 1998). San Diego, CA: American Society of Hematology. 2016 Singhal, D., Strupp, C., Chhetri, R., Kutyna, M. M., Wee, L. A., Nath, S. V., . . . Germing, U. (2016). RBC-Transfusion Dependency Improves the Prognostic Value of the Revised-IPSS in MDS Patients: Analysis of South Australian and Dusseldorf MDS Registries. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY. 2016 Singhal, D., Wee, L. A., Parker, W. T., Moore, S., Babic, M., Feng, J., . . . Hiwase, D. K. (2016). The Frequency of Genetic Mutations in T-MN Is High and Comparable to Primary MDS but the Spectrum Is Different. In BLOOD Vol. 128 (pp. 5 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI2015 Singhal, D., Hague, S., Roxby, D., Wee, L. A., Lee, O. -L., Sinha, R., . . . Hiwase, D. K. (2015). RBC Alloimmunization Burden Is High in Regularly RBC-Transfused Myelodysplastic Syndrome (MDS) Patients: A Report from South Australian-MDS Registry. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. 2015 Hahn, C. N., Babic, M., Schreiber, A. W., Kutyna, M. M., Wee, L. A., Brown, A. L., . . . Hiwase, D. (2015). Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome. In BLOOD Vol. 126 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS32015 Hoi, P. J., Hiwase, D., Ramakrishna, A., Viiala, N., Ross, D. M., Zor, E., & Gervasio, O. L. (2015). Prevalence of Cardiac and H sis in Australian Patients with Transfusion-Dependent Anemias or No -Dependent Thalassemia, As Assessed By MRI (the TIMES study). In BLOOD Vol. 126 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY. 2015 Hiwase, D., Hahn, C., Babic, M., Moore, S., Singhal, D., Kutyna, M., . . . Scott, H. (2015). MULTIPLE MUTATIONS IN THE SAME GENE SUGGEST CLONAL DIVERSITY AND IS ASSOCIATED WITH POOR PROGNOSIS IN MDS. In LEUKEMIA RESEARCH Vol. 39 (pp. S77-S78). Washington, DC: PERGAMON-ELSEVIER SCIENCE LTD.
DOI2015 Hiwase, D., Moore, S., Kutyna, M., Fraser, R., Singhal, D., Chhetri, R., . . . Scott, H. (2015). SNP-MICROARRAY OF PERIPHERAL BLOOD-GRANULOCYTES DNA CAN DETECT CLONAL EVOLUTION IN MYELODYSPLASTIC SYNDROMES (MDS). In LEUKEMIA RESEARCH Vol. 39 (pp. S79-S80). Washington, DC: PERGAMON-ELSEVIER SCIENCE LTD.
DOI2015 Kenealy, M., Benson, W., Stevenson, W., Eek, R., Zantomio, D., Cunningham, I., . . . Seymour, J. F. (2015). THE ADDITION OF LENALIDOMIDE TO AZACITIDINE ACHIEVES HIGHER RESPONSES BUT NO IMPROVEMENT IN TWELVE MONTH CLINICAL BENEFIT OR PFS; MAIN ANALYSIS AUSTRALIAN ALLG MDS4 TRIAL. In LEUKEMIA RESEARCH Vol. 39 (pp. S5). Washington, DC: PERGAMON-ELSEVIER SCIENCE LTD.
DOI WoS32015 Hiwase, D., Moore, S., Hahn, C., Kutyna, M., Van der Hoek, M., Fraser, R., . . . Scott, H. (2015). TARGETED MUTATION SEQUENCING AND SNP-MICRORRAY CAN IDENTIFY POOR PROGNOSTIC GROUP IN IPSS-LOWER RISK GROUP. In LEUKEMIA RESEARCH Vol. 39 (pp. S78-S79). Washington, DC: PERGAMON-ELSEVIER SCIENCE LTD.
DOI2013 Hiwase, D. K., Kutyna, M. M., Chhetri, R., Howell, S., Harrison, P. B., Nath, S. V., . . . To, L. B. (2013). Transfusion Dependency Is Associated With Inferior Survival Even In Very Low and Low Risk IPSS-R Patients. In BLOOD Vol. 122 (pp. 2 pages). New Orleans, LA: AMER SOC HEMATOLOGY.
DOI WoS52011 Chow, A. W. S., Lee, C. H. S., Hiwase, D. K., To, L. B., & Horvath, N. (2011). Relapsed Multiple Myeloma: Who Benefits From Salvage Autografts?. In BLOOD Vol. 118 (pp. 1319). San Diego, CA: AMER SOC HEMATOLOGY. 2011 Yeung, D. T., Osborn, M., White, D. L., Branford, S., Kornhauser, M., Slader, C., . . . Hughes, T. P. (2011). Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial. In BLOOD Vol. 118 (pp. 208). San Diego, CA: AMER SOC HEMATOLOGY.
WoS12011 Nievergall, E., White, D. L., Ramshaw, H., Lopez, A. F., Hughes, T. P., & Hiwase, D. K. (2011). Antibody-Targeting of IL-3 Receptor-α Increases the Susceptibility of CD34<SUP>+</SUP> CML Progenitors to Dasatinib-Induced Cell Death. In BLOOD Vol. 118 (pp. 1599). San Diego, CA: AMER SOC HEMATOLOGY.
DOI WoS12010 Yeung, D. T., Osborn, M., White, D. L., Branford, S., Haswell, L., Slader, C., . . . Hughes, T. (2010). Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial. In BLOOD Vol. 116 (pp. 96). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS102010 Yeung, D., Osborn, M., White, D., Branford, S., Haswell, L., Slader, C., . . . Hughes, T. (2010). Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDELL-II trial. In Proceedings of 2010 American Society of Hematology conference (pp. 1-2). Florida. 2010 Hiwase, D. K., Engler, J., Saunders, V., White, D. L., & Hughes, T. (2010). In Contrast to Imatinib, Dasatinib Intracellular Concentration In CML-CD34<SUP>+</SUP> Progenitors Is Not Significantly Different Than That Observed In CD34<SUP>-</SUP> Mature Cells.. In BLOOD Vol. 116 (pp. 517). Orlando, FL: AMER SOC HEMATOLOGY. 2010 Hiwase, D. K., Eadie, L., Saunders, V., Hughes, T., & White, D. L. (2010). Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition.. In BLOOD Vol. 116 (pp. 1626-1627). Orlando, FL: AMER SOC HEMATOLOGY.
WoS12010 Hiwase, D. K., Eadie, L., Saunders, V., Hughes, T., & White, D. L. (2010). Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition. In Blood Vol. 116 (pp. 3991). American Society of Hematology.
DOI2009 Hiwase, D. K., White, D. L., Powell, J. A., Saunders, V. A., Zrim, S., Frede, A., . . . Hughes, T. (2009). Blocking of Cytokine Survival Signals along with Intense Bcr-Abl Kinase Inhibition May Eradicate CML Progenitor Cells. In BLOOD Vol. 114 (pp. 1258-1259). New Orleans, LA: AMER SOC HEMATOLOGY. 2008 Hiwase, D. K., White, D. L., Saunders, V. A., Melo, J. V., Kumar, S., & Hughes, T. P. (2008). Short-Term Intense Bcr-Abl Kinase Inhibition Is Adequate to Trigger Cell Death in CML Cell Lines but Not in CML-CD34+Cells Unless They Are Growth Factor Deprived. In BLOOD Vol. 112 (pp. 397). San Francisco, CA: AMER SOC HEMATOLOGY. 2007 Hiwase, D. K., White, D. L., Saunders, V. A., Dang, P., Venables, A., Eadie, L., . . . Hughes, T. P. (2007). In contrast to imatinib, OCT-1 mediated influx has minimal impact on cellular uptake of dasatinib in CML patients at diagnosis. In BLOOD Vol. 110 (pp. 575A-576A). Atlanta, GA: AMER SOC HEMATOLOGY.
WoS72007 Hiwase, D. K., White, D. L., Saunders, V. A., Dang, P., Venables, A., Eadie, L., . . . Hughes, T. P. (2007). In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis.. In Blood Vol. 110 (pp. 1937). American Society of Hematology.
DOI -
Conference Items
Year Citation 2019 Hong, L. E., Singhal, D., Wee, A., Chhetri, R., Kutyna, M., Wechalekar, M., . . . Proudman, S. (2019). MUTATIONAL LANDSCAPE OF MYELODYSPLASTIC SYNDROME IN PATIENTS WITH AUTOIMMUNE RHEUMATOLOGICAL DISORDERS. Poster session presented at the meeting of ANNALS OF THE RHEUMATIC DISEASES. Madrid, SPAIN: BMJ PUBLISHING GROUP.
DOI2019 Kutyna, M. M., Wee, A., Paton, S., Cakouros, D., Arthur, A., Chhetri, R., . . . Hiwase, D. K. (2019). Aberrant Bone Marrow Microenvironment in Therapy Related Myeloid Neoplasm (t-MN). Poster session presented at the meeting of BLOOD. FL, Orlando: ELSEVIER.
DOI WoS22018 Shanmuganathan, N., Branford, S., Yong, A. S. M., Hiwase, D. K., Yeung, D. T., Ross, D. M., & Hughes, T. P. (2018). The e13a2 BCR-ABL1 Transcript Is Associated with Higher Rates of Molecular Recurrence after Treatment-Free Remission Attempts: Retrospective Analysis of the Adelaide Cohort. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY.
DOI WoS82018 Molga, A., Wall, M., Chhetri, R., Wee, A., Singhal, D., Singhal, N., . . . Hiwase, D. K. (2018). Geriatric Assessment in Older People with Myelodysplasia Is Predictive of Azacitidine Therapy Completion and Survival: A Prospective Interventional Study at the Royal Adelaide Hospital. Poster session presented at the meeting of BLOOD. CA, San Diego: AMER SOC HEMATOLOGY.
DOI WoS22018 Singhal, D., Wee, A., Kutyna, M. M., Babic, M., Chhetri, R., Parker, W., . . . Hiwase, D. K. (2018). Therapy-Related Myeloid Neoplasms (T-MN) and Primary MDS (PMDS) Patients with Very Low (VL) or Low (L) IPSS-R Score Share Clinical and Biological Characteristics and Have Similar Outcome. Poster session presented at the meeting of BLOOD. CA, San Diego: AMER SOC HEMATOLOGY.
DOI2018 Hong, L. E., Singhal, D., Wee, A., Chhetri, R., Wechalekar, M. D., Proudman, S., & Hiwase, D. K. (2018). The Mutation Profile of Myelodysplastic Syndrome Associated with Auto-Immune Rheumatological Disorders. Poster session presented at the meeting of BLOOD. CA, San Diego: AMER SOC HEMATOLOGY.
DOI2018 Pradhan, A., Chhetri, R., Wee, A., Malhotra, R., Singhal, D., Nelson, R., . . . Hiwase, D. K. (2018). Causative Organisms and Resistance Patterns of Infection in Patients with Myelodysplastic Syndrome (MDS): A 20 Year Retrospective Analysis. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY.
DOI2018 Chhetri, R., Wee, A., Sinha, R., Kutyna, M. M., Gupta, S., Nath, L., . . . Hiwase, D. K. (2018). Red Cell Alloimmunisation Is Associated with Increased Red Cell Transfusion Requirements in Myelodysplastic Syndrome. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY.
DOI WoS12017 Singhal, D., Wee, L. A., Babic, M., Parker, W., Moore, S., Feng, J., . . . Hiwase, D. (2017). THERAPY RELATED MYELOID NEOPLASMS (T-MN) SHOW HIGH MUTATION FREQUENCY AND A SPECTRUM DIFFERENT FROM PRIMARY MDS. Poster session presented at the meeting of LEUKEMIA RESEARCH. Valencia, SPAIN: PERGAMON-ELSEVIER SCIENCE LTD.
DOI2017 Singhal, D., Chhetri, R., Wee, L. A., Kutyna, M., Nath, S., & Hiwase, D. (2017). IRON CHELATION THERAPY IS ASSOCIATED WITH IMPROVED SURVIVAL IN LOWER RISK MDS. Poster session presented at the meeting of LEUKEMIA RESEARCH. Valencia, SPAIN: PERGAMON-ELSEVIER SCIENCE LTD.
DOI2016 Singhal, D., Moore, S., Kutyna, M., Chhetri, R., Wee, L. A., Gray, J., . . . Hiwase, D. (2016). THERAPY RELATED MYELOID NEOPLASM FOLLOWING RADIOTHERAPY HAS HIGHER INCIDENCE OF POOR RISK CYTOGENETICS AND ARE ASSOCIATED WITH POOR SURVIVAL COMPARED TO DE NOVO MDS CASES. Poster session presented at the meeting of HAEMATOLOGICA. Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. 2016 Watts, S., Saunders, V., Wee, A., Kutyna, M., White, D. L., Hughes, T., & Hiwase, D. (2016). Understanding the mechanism of secondary resistance to Azacitidine in Myelodysplastic syndromes using the cell-line model MOLM-13. Poster session presented at the meeting of Poster Session. Adelaide, SA. 2016 Watts, S., Wee, A., Saunders, V., Kutyna, M., White, D. L., Hughes, T., & Hiwase, D. (2016). Determining Mechanisms of Resistance to Azacitidine (Aza) in Myelodysplastic (MDS) Syndromes and Acute Myeloid Leukaemia (AML) using an in-vitro model. Poster session presented at the meeting of Poster Session. Melbourne, VIC. 2016 Ho, P. J., Hiwase, D., Ramakrishna, R., Viiala, N., Ross, D., Zor, E., . . . Bowden, D. K. (2016). THE IMPACT OF CARDIAC AND HEPATIC MRI ASSESSMENT ON THE CLINICAL MANAGEMENT OF AUSTRALIAN PATIENTS WITH TRANSFUSION DEPENDENT ANEMIAS OR NON-TRANSFUSION-DEPENDENT THALASSEMIA IN THE TIMES STUDY. Poster session presented at the meeting of HAEMATOLOGICA. Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. 2014 Kenealy, M., Benson, W., Stevenson, W., Eek, R., Zantomio, D., Cunningham, I., . . . Seymour, J. F. (2014). THE ADDITION OF LENALIDOMIDE TO AZACITIDINE IN HIGHER RISK MDS IS DELIVERABLE WITH HIGHER RESPONSE RATES; FIRST ANALYSIS OF THE ALLG MDS4 RANDOMISED PHASE II STUDY. Poster session presented at the meeting of HAEMATOLOGICA. Milan, ITALY: FERRATA STORTI FOUNDATION. 2014 Nievergall, E., Reynolds, J., Kok, C. H., Watkins, D., Biondo, M., Busfield, S. J., . . . Hughes, T. P. (2014). High plasma levels of TGF-α and IL-6 at diagnosis predict early molecular response failure and transformation in CML. Poster session presented at the meeting of Abstract of presentation to 56th ASH Annual Meeting, published in Blood. San Francisco, California: American Society of Hematology.
DOI WoS12014 Hiwase, D. K., Singhal, D., Chhetri, R., Kutyna, M. M., Harrison, P. B., Nath, S. V., . . . To, L. B. (2014). Inclusion of RBC-Transfusion Dependency Can Improve the Prognostic Value of Revised-IPSS in MDS Patients. Poster session presented at the meeting of BLOOD. San Francisco, CA: AMER SOC HEMATOLOGY. 2013 Hiwase, D., Kutyna, M., Carr, T., Harrison, P., Melo, J. V., Bardy, P., & To, L. B. (2013). Transfusion dependency is associated with inferior outcome in very low- and low-risk IPSS-R patients. Poster session presented at the meeting of LEUKEMIA RESEARCH. PERGAMON-ELSEVIER SCIENCE LTD.
DOI2013 Kenealy, M., Seymour, J. F., Benson, W., Stevenson, W., Eek, R., Zantomio, D., . . . Zannino, D. (2013). The combination of azacitidine and lenalidomide is deliverable without unexpected toxicity; interim safety results of the ALLG MDS4 randomised trial. Poster session presented at the meeting of LEUKEMIA RESEARCH. PERGAMON-ELSEVIER SCIENCE LTD.
DOI WoS12013 Hiwase, D., Yeung, D., Carne, L., Ross, D., Grigg, A., & Hughes, T. (2013). Hypercholesterolemia In Imatinib Intolerant/Resistant CML-CP Patients Treated With Nilotinib: A Retrospective Analysis. Poster session presented at the meeting of Blood. Amer Soc Hematology.
WoS102013 White, D. L., Schafranek, L., Nievergall, E., Powell, J. A., Hiwase, D., Leclercq, T., & Hughes, T. (2013). STAT5 is a critical component of the time-dependent sensitivity of CML cells to TKI treatment in a Bcr-Abl-dependent, but JAK2-independent manner.. Poster session presented at the meeting of American Society of Haematology. New Orleans, USA. 2012 Amin, T., Elias, T., Hiwase, D., & Otto, S. (2012). SYSTEMIC MASTOCYTOSIS IS ASSOCIATED WITH MINIMAL CHANGE DISEASE. Poster session presented at the meeting of NEPHROLOGY. WILEY-BLACKWELL. 2012 Nievergall, E., White, D. L., Yong, A. S. M., Ramshaw, H. S., Busfield, S. J., Vairo, G., . . . Hiwase, D. K. (2012). Effective Elimination of CML Progenitor and Stem Cells Through Combination of α-CD123 Antibody-Dependent Cell-Mediated Cytotoxicity and Tyrosine Kinase Inhibitor Treatment. Poster session presented at the meeting of BLOOD. GA, Atlanta: AMER SOC HEMATOLOGY.
DOI2012 Schafranek, L., Nievergall, E., Powell, J. A., Hiwase, D. K., White, D. L., & Hughes, T. P. (2012). Commitment of CML Cells to Apoptotic Cell Death Depends On the Length of Exposure to Das and the Level of STAT5 Activity. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY.
DOI WoS32012 Yeung, D. T., Osborn, M. P., White, D. L., Branford, S., Kornhauser, M., Slader, C., . . . Hughes, T. P. (2012). Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY.
DOI WoS8
- Molecular pathogenesis of bone marrow failure and drug resistance in MDS and therapy-related myeloid neoplasms. Miller Bequest HSCGB (2020). $30,800. Devendra Hiwase.
- Molecular pathogenesis of bone marrow failure and drug resistance in MDS and therapy-related myeloid neoplasms. Sail for Cancer HSCGB (2020). $30,000. Devendra Hiwase.
- Precision Medicine for Chronic Myelomonocytic Leukaemia: A phase II Trial Studying the Efficacy of Lenzilumab and High Dose Ascorbate with Azacitidine Based on Molecular Profiling Compared to Risk-matched Historical Cohort. MRFF Rare Cancers, Rare Diseases and Unmet Need APP1201012 (2019). $1,619,122. Timothy Hughes, Devendra Hiwase, David Ross, Daniel Thomas, David Yeung, Steven Lane, Agnes Yong, Angel Lopez, Timothy Hercus, John Reynolds.
- Understanding molecular pathogenesis of therapy related myeloid neoplasm. MRFF Investigator Grants MRF1195517 (2019). $560,105. Devendra Hiwase
- South Australian MDS-Database. Grant Funding, Novartis Pharmaceuticals Australia Pty Limited (2018). $60,000. Devendra Hiwase
- To evaluate the frequency of clonal haematopoiesis and risk of therapy-related myeloid neoplasm in primary cancer patients treated with chemo/radiotherapy. RAH Research Committee Clinical Project Grant (2018). $50,000. Nimit Singhal, Deepak Singhal, Devendra Hiwase, Chris Hahn, Hamish Scott
- Molecular pathogenesis of bone marrow failure and drug resistance in MDS. Miller Bequest HSCGB (2018). $75,886.50. Devendra Hiwase.
- Determine the clinical impact of mutation profile in ICUS, MDS and t-MN. Sail for Cancer HSCGB (2018). $38,220.67. Devendra Hiwase.
- Molecular profiling to improve diagnosis and develop therapeutic strategy for MDS/MPN overlap syndrome. Miller Bequest HSCGB (2017). $73,718. Ian Lewis, Devendra Hiwase, Amilia Wee
- Molecular Profiling of Idiopathic Cytopenia Undetermined Significance to Improve Diagnosis and Develop Prognostic Model. Sail for Cancer HSCGB (2017). $54,345. Ian Lewis, Devendra Hiwase, Amilia Wee
I lead the MDS/AML research group in the South Australian Health and Medical Institute (SAHMRI) and supervise a research assistant, data manager, senior nurse, two PhD students, advanced trainee registrars and medical students. I am actively involved teaching medical students and was awarded “Best teacher of the year” by the University of Adelaide.
-
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2024 Principal Supervisor The burden of cure: Secondary malignancy after allogeneic haematopoietic stem cell transplant Doctor of Philosophy Doctorate Full Time Miss Alia Elizabeth Cibich 2024 Co-Supervisor Investigating the association between seronegative rheumatoid arthritis, calcium pyrophosphate deposition disease and myeloid neoplasms. Doctor of Philosophy Doctorate Part Time Dr Lih En Hong 2023 Co-Supervisor Novel Target Discovery for TP53 Mutated clonal Haematopoiesis Doctor of Philosophy Doctorate Full Time Mr Hossein Anani 2023 Principal Supervisor Role of Inherited and Acquired Genetic Changes in the Molecular Pathogenesis of Therapy-Related Myeloid Neoplasms Doctor of Philosophy Doctorate Full Time Dr Deepak Singhal 2022 Co-Supervisor A humanized monocyte model of TET2 mutated clonal hematopoiesis for noel target discovery Doctor of Philosophy Doctorate Full Time Miss Maha Kamel 2019 Co-Supervisor Frailty in Patients with Haematological Malignancies Doctor of Philosophy Doctorate Part Time Dr Angela Teresa Molga -
Past Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2018 - 2022 Co-Supervisor Evaluating the Role of Bone Marrow Microenvironment in the Pathogenesis of Therapy-related Myeloid Neoplasms Doctor of Philosophy Doctorate Full Time Mrs Monika Maria Kutyna
Connect With Me
External Profiles
